Glutaminase 1 plays critical roles in myelodysplastic syndrome and acute myeloid leukemia cells

• Published in: Cancer biomarkers : section A of Disease markers Vol. 41; no. 1; pp. 55 - 68
• Main Authors: Okabe, Seiichi, Moriyama, Mitsuru, Arai, Yuya, Gotoh, Akihiko
• Format: Journal Article
• Language: English
• Published: Netherlands IOS Press BV 01.01.2024; IOS Press
• Subjects: Acute myeloid leukemia; Amino acids; Apoptosis - drug effects; Bcl-2 protein; Benzeneacetamides - pharmacology; Benzylidene Compounds - pharmacology; Bone marrow; Bridged Bicyclo Compounds, Heterocyclic - pharmacology; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Caspase; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Effectiveness; Gene expression; Glutaminase; Glutaminase - antagonists & inhibitors; Glutaminase - genetics; Glutaminase - metabolism; Glutamine; Humans; Hypoxia; Inhibitors; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Lymphocytes B; Lymphoma; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - metabolism; Myelodysplastic Syndromes - pathology; Proteasomes; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Statistical analysis; Sulfides; Sulfonamides - pharmacology; Thiadiazoles - pharmacology; Transfection; Variance analysis; AML; hypoxia; Glutaminolysis; MDS; BCL-2 inhibitor; GLS inhibitor
• ISSN: 1574-0153; 1875-8592; 1875-8592
• DOI: 10.3233/CBM-230454

Myelodysplastic syndrome (MDS) features bone marrow failure and a heightened risk of evolving into acute myeloid leukemia (AML), increasing with age and reducing overall survival. Given the unfavorable outcomes of MDS, alternative treatments are necessary. Glutamine, the most abundant amino acid in the blood, is metabolized first by the enzyme glutaminase (GLS). To investigate whether GLS is involved in the progression of MDS. The efficacy of GLS inhibitors (CB839 or IPN60090) and BCL2 inhibitor venetoclax was also examined. We employed GLS inhibitors (CB839, IPN60090) and the BCL2 inhibitor venetoclax, prepared as detailed. MDS and AML cell lines were cultured under standard and modified (hypoxic, glutamine-free) conditions. Viability, proliferation, and caspase activity were assessed with commercial kits. RT-PCR quantified gene expression post-shRNA transfection. Mitochondrial potential, ATP levels, proteasome activity, and metabolic functions were evaluated using specific assays. Statistical analyses (t-tests, ANOVA) validated the findings. The glutamine-free medium inhibited the growth of MDS cells. GLS1 expression was higher in AML cells than in normal control samples (GSE15061), whereas GLS2 expression was not. Treatment of MDS and AML cells for 72 h was inhibited in a dose-dependent manner by GLS inhibitors. Co-treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax and GLS inhibitors increased potency. Cells transfected with GLS1 short hairpin RNA showed suppressed proliferation under hypoxic conditions and increased sensitivity to venetoclax. Targeting glutaminolysis and BCL2 inhibition enhances the therapeutic efficacy and has been proposed as a novel strategy for treating high-risk MDS and AML.